Claims
- 1. A compound of the formula (I) or a pharmaceutically acceptable salt or ester thereof: ##STR100## wherein each of ##STR101## which are the same or different, is selected from the group consisting of phenyl, naphthyl, anthryl and heteroaromatic ring group which is a 5- or 6-membered monocyclic ring which contains a heteroatom selected from the group consisting of --O--, --S-- and --N--; A is a C.sub.2-8 saturated or unsaturated aliphatic hydrocarbon group which is unsubstituted or substituted by lower alkyl, hydroxyl, lower hydroxyalkyl, lower alkoxy, carboxyl, lower carboxyalkyl, phenyl, naphthyl or anthryl or alkyl-substituted phenyl, naphthyl or anthryl; both X and Y are --CHR.sup.a --, wherein R.sup.a is hydrogen or lower alkyl, or X and Y together represent vinylene or ethynylene; each of R.sup.1, R.sup.2, R.sup.3, R.sup.8 and R.sup.9, which are the same or different, is hydrogen, halogen, hydroxyl, lower alkyl or lower alkoxy; each of R.sup.4 and R.sup.5 which are the same or different is hydrogen, halogen, hydroxyl, amino, nitro, cyano, carboxyl, lower alkoxycarbonyl, carbamoyl, lower alkylcarbamoyl, lower alkyl, lower hydroxyalkyl, lower fluoroalkyl or lower alkoxy; R.sup.6 is lower alkyl; and R.sup.7 is hydrogen or lower alkyl.
- 2. The compound of claim 1, wherein A is a group of the formula: ##STR102## wherein R.sup.10 is hydrogen, hydroxyl, lower hydroxyalkyl, lower alkoxy or carboxyl; R.sup.11 is hydrogen, hydroxyl, lower alkoxy, carboxyl or lower carboxyalkyl; R.sup.12 is hydrogen, lower hydroxyalkyl or carboxyl; R.sup.13 is hydrogen, hydroxyl or carboxyl; each of m and n which are the same or different, is an integer of from 0 to 2.
- 3. The compound of claim 1, wherein A is a group of the formula: ##STR103## wherein R.sup.12 is hydrogen, lower hydroxyalkyl or carboxyl; R.sup.13 is hydrogen, hydroxyl or carboxyl; p is 0 or 1; and each of q and r, which are the same or different, is an integer of from 0 to 2.
- 4. The compound of claim 1, wherein each of ##STR104## which are the same or different, is selected from the group consisting of phenyl, naphthyl and anthryl.
- 5. The compound of claim 1, wherein each of ##STR105## which are the same or different, is selected from the group consisting of phenyl, naphthyl and anthryl; and ##STR106## is a heteroaromatic ring group which is a 5- or 6-membered monocyclic ring which contains --O--, --S-- or --N--.
- 6. The compound of claim 1, wherein ##STR107## is a heteroaromatic ring group which is a 5- or 6-membered monocyclic ring which contains --O--, --S-- or --N--; and each of ##STR108## which are the same or different, is selected from the group consisting of phenyl, naphthyl and anthryl.
- 7. The compound of claim 1, wherein each of ##STR109## which are the same or different, is a heteroaromatic ring group which is a 5- or 6-membered monocyclic ring which contains --O--, --S-- or --N--; and each of ##STR110## which are the same or different, is selected from the group consisting of phenyl, naphthyl and anthryl.
- 8. The compound of claim 1, wherein said heteroaromatic ring group which is a 5- or 6-membered memocyclic ring which contains --O--, --S-- or --N-- is selected from the group consisting of pyrolyl, imidazolyl, pyrozolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, isooxazolyl, furyl, thienyl, thiazolyl, isothiazolyl, indolyl, benzo furanyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzisothiazolyl, indazolyl, purinyl, quinolyl, isoquinolyl, phthalazinyl, naphthyldinyl, quinoxalinyl, quinazolinyl, cinnolinyl and pteridinyl.
- 9. The compound of claim 8, wherein said heteroaromatic ring roup which is a 5- or 6-membered monocyclic ring which contains --O--, --S-- or --N-- is selected from the group consisting of furyl, thienyl, pyridyl, pyrimidinyl, oxazolyl, isooxazolyl, thiazolyl, benzolfuronyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzothiazolyl and quinolyl.
- 10. The compound of claim 1, wherein lower alkyl for R.sup.a or any one of R.sup.1 -R.sup.9 is methyl or ethyl.
- 11. The compound of claim 1, wherein lower hydroxyalkyl for either R.sup.4 or R.sup.5 is hydroymethyl or hydroxyethyl.
- 12. The compound of claim 1, wherein lower alkoxy for any one of R.sup.1 -R.sup.5, R.sup.8 or R.sup.9 is methoxy, ethoxy or methylenedioxy.
- 13. The compound of claim 1, wherein lower fluoroalkyl for either R.sup.4 or R.sup.5 is fluoromethyl, difluoromethyl, trifluoromethyl, 1-fluoroethyl, 2-fluoromethyl, 2,2,2-trifluoroethyl or pentafluoroethyl.
- 14. An anti-tumor agent, which comprises a compound of claim 1 or a pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable excipient.
Priority Claims (1)
Number |
Date |
Country |
Kind |
6-212147 |
Aug 1994 |
JPX |
|
Parent Case Info
This application is a division of application Ser. No. 08/616,464, filed Mar. 15, 1996 allowed, now U.S. Pat. No. 5,849,747, which is a Continuation-In-Part of International Application No. PCT/JP95/01589 filed on Aug. 10, 1995.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
5260465 |
Singh et al. |
Nov 1993 |
|
5340828 |
Graham et al. |
Aug 1994 |
|
5488149 |
Nomoto et al. |
Jan 1996 |
|
Foreign Referenced Citations (6)
Number |
Date |
Country |
0 535 730 |
Apr 1993 |
EPX |
0 547 670 |
Jun 1993 |
EPX |
0 776 884 |
Jun 1997 |
EPX |
5-213992 |
Aug 1993 |
JPX |
5-279290 |
Oct 1993 |
JPX |
WO 9701275 |
Jan 1997 |
WOX |
Divisions (1)
|
Number |
Date |
Country |
Parent |
616464 |
Mar 1996 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
PCTJP9501589 |
Aug 1995 |
|